Skip to content
Calculator
Regulatory

Peptide laws by country

Last updated: October 3, 2026 · 4 min read · By the Grey Peptides Editorial Board

Sydney Harbour Bridge with sailboats on the harbour
Photo by Donovan Kelly on Pexels
Grey Peptides
Grey Peptides Editorial Board
Every status on this page carries the date it was checked. How we work
Key takeaways
  • Each page is built from the regulator's own published position, with the date we read it.
  • Tracker tables are generated from our regulatory dataset, so a status changes in one place.

Countries

  • Peptide laws in Australia: Australia regulates peptides more tightly than most countries: BPC-157, TB-500, ipamorelin, CJC-1295 and other growth hormone peptides are Schedule 4 medicines that are illegal to possess without authority, and the TGA seizes poorly labelled imports.
  • Peptide laws in Brazil: On July 2, 2026, Brazil's health regulator ANVISA stated that injectable peptides such as GHK-Cu, BPC-157, TB-500, CJC-1295 and ipamorelin are not registered in any category, food, medicine, supplement or cosmetic, and so are illegal for any health or aesthetic use. Approved peptide medicines such as semaglutide and tirzepatide are a different matter.
  • Peptide laws in Canada: Health Canada treats most injectable peptides as prescription drugs and has seized peptides from online sellers, clinics and gyms. Here is what is authorised, what 'research use only' means there, and how importing works.
  • Peptide laws in China: China's revised drug regulations took effect on May 15, 2026. They bar online retail of high-risk medicines and stop doctors prescribing those drugs in online consultations, which closed the route by which GLP-1 injections were bought for weight loss. Research peptides are not approved medicines in China.
  • Peptide laws in the European Union: In the EU, peptide medicines are authorised centrally by the EMA or by national agencies, and enforcement against illegal ones is national. EMA warned in 2025 of a sharp rise in illegal GLP-1 products sold online; research peptides have no EU authorisation.
  • Peptide laws in France: France's medicines agency, the ANSM, told the public in July 2026 not to buy or use peptides sold online, naming retatrutide, BPC-157, TB-500 and GHK-Cu, after reports of serious adverse effects. Approved peptides such as semaglutide remain prescription medicines.
  • Peptide laws in Germany: Germany treats approved peptides as prescription medicines, like the rest of the EU, but adds a criminal law most countries lack: its Anti-Doping Act bans acquiring or possessing 'non-small amounts' of listed doping substances, including growth hormone peptides, for doping in sport.
  • Peptide laws in Ireland: Ireland's medicines regulator, the HPRA, polices prescription medicines including GLP-1s, has repeatedly warned against buying them outside pharmacies, and seizes hundreds of thousands of doses of illegal medicines a year. Research peptides have no Irish or EU authorisation.
  • Peptide laws in Japan: Japan's health ministry (MHLW) issued a notice on June 16, 2026 against off-label cosmetic and weight-loss use of GLP-1 and GIP/GLP-1 drugs. Japan allows limited personal import of medicines, but prescription drugs are capped at one month's supply and syringes need a prescription. No research peptide is an approved medicine in Japan.
  • Peptide laws in Mexico: Mexico regulates medicines through COFEPRIS, and approved peptides such as semaglutide need a prescription. COFEPRIS has warned against buying GLP-1 drugs online. Research peptides fall into a legal gap that a July 2026 bill in the Chamber of Deputies proposes to close with an outright ban on sale to the public.
  • Peptide laws in the Netherlands: In August 2026 the Dutch Health and Youth Care Inspectorate (IGJ) ordered an online seller to stop selling retatrutide, tirzepatide and semaglutide, after reports of harm from retatrutide and from counterfeit GLP-1s. Approved peptides are prescription medicines.
  • Peptide laws in New Zealand: New Zealand classified BPC-157 as a prescription medicine in 2023, which makes importing it without a prescription unlawful, and Medsafe has asked for whole groups of peptides to be classified the same way. Medsafe warned in 2026 about unapproved peptides sold online, including retatrutide.
  • Peptide laws in Thailand: Thailand reclassified injectable GLP-1 medicines as specially controlled drugs with effect from September 15, 2026, so a pharmacy may dispense them only against a doctor's prescription. Research peptides are unregistered medicines, which cannot lawfully be sold or imported for sale.
  • Peptide laws in the United Arab Emirates: The UAE runs one of the stricter medicine-import systems in the region, with permits for controlled medicines and quantity limits for personal use. In 2026 its drug regulator acted against 71 sources selling unapproved peptide products for weight loss and stated that retatrutide is not approved for use.
  • Peptide laws in the United Kingdom: In the UK, peptides like semaglutide are licensed prescription medicines, while BPC-157 and most research peptides have no UK licence. The MHRA says peptides sold with medicinal claims are medicines, and it opened an investigation into peptide clinics in April 2026.

Frequently asked questions

Are peptides legal everywhere the same way?

No. Approved peptide medicines are prescription-only in most countries, but rules on research peptides, importing and possession differ sharply; Australia, for example, makes possession of several without authority illegal.

Sources

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.

All countries

New guides and rule changes, by email

One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.

We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead